Wantai Biopharm has launched China's first domestically developed 9-valent human papillomavirus (HPV) vaccine at RMB 499 per dose, approximately 40% of imported vaccine prices, following national lot release certification earlier this month. The vaccine demonstrates equivalent immunogenicity and safety to MSD's alternative in head-to-head trials published in The Lancet Infectious Diseases, with superior neutralizing antibody levels against HPV types 52 and 58 that are prevalent in Chinese women.

Clinical data from 11,000 participants showed 100% efficacy against persistent infection from seven high-risk HPV types covering 95.4% of China's cervical cancer cases. The two-dose regimen for adolescents aged 9 to 17 improves accessibility, while the expanded age range to 45 addresses China's unique bimodal HPV infection pattern peaking at 15-24 and 40-44 years. Experts project 70% vaccination coverage could accelerate China's cervical cancer elimination target from 2077 to 2050.

PharmCube's NextBiopharm® database reveals that vaccines are the most sought-after modality against HPV among dozens of strategies currently under research (top 10 shown below). Click here to request a free trial for NextBiopharm®.